The results show that the two test vaccines, cAd3-EBOZ and rVSV-ZEBOV, pose no major safety concerns and can produce immune responses within one month after vaccination that last for at least one year. From February 2 through April 30, 2015, PREVAIL enrolled 1,500 men and women ages 18 and older in the study. One group received one test vaccine, the second group the other test vaccine, and the third group received a placebo (saltwater injection). It was important to include the placebo so that the research team could, compare how well the test vaccines worked. Some participants who received the test vaccines had temporary mild to moderate side effects, including headaches, muscle pain, fever and fatigue.

Source: Front Page Africa October 12, 2017 04:07 UTC